丹参酮ⅡA纳米结构脂质载体的处方优化及其体外透皮研究

详细信息    查看官网全文

• 英文论文题名：Preparation of Tan ⅡA loaded nanostructured lipid carrier and its in vitro transdermal diffusion characteristics
• 论文作者：沈成英 ; 郑娟 ; 庞建云 ; 徐方楚 ; 廖卫波 ; 袁海龙
• 英文论文作者：SHEN cheng-ying ; ZHENG juan ; PANG jian-yun ; XU fangchu ; LIAO wei-bo ; YUAN Hai-long ; The General Hospital of Air Force
• 年：2016
• 作者机构：中国人民解放军空军总医院;
• 论文关键词：丹参酮ⅡA ; 纳米结构脂质载体 ; Box-Behnken设计 ; 体外透皮 ; 皮肤滞留量
• 英文论文关键词：Tan ⅡA ; nanostructured lipid carrier ; Box-Behnken design ; in vitro transdermal absorption ; skin retention
• 会议召开时间：2016-09-27
• 会议录名称：中国药学会第十三届青年药学科研成果交流会论文集
• 语种：中文
• 分类号：R283.6
• 学会代码：YYWS
• 会议名称：中国药学会第十三届青年药学科研成果交流会
• 会议地点：中国江西南昌
• 主办单位：中国药学会
• 学会名称：中国药学会
• 页数：9
• 文件大小：1420k
• 原文格式：O
• 会议级别：全国

摘要

为研制丹参酮ⅡA纳米结构脂质载体(Tan ⅡA-NLC),并进行体外透皮研究。本文采用高压均质技术制备Tan ⅡA-NLC,运用Box-Behnken设计-效应面法优化处方,并对其进行表征。采用Franze扩散池法评价Tan HA-NLC体外透皮性能。结果显示,以最优处方:脂药比为88、固液脂质比为2、稳定剂用量为1%,制得的Tan ⅡA-NLC粒径为182±14 nm,多分散指数(PDI)为0.1906±0.0245,Zeta电位-27.8±5.4 mV,包封率(EE)为86.44±9.26%,载药量(DL)为0.98±0.18%;体外透皮吸收实验结果显示TanⅡA-NLC的24h药物累积透皮量低于溶液,但其在表皮中的滞留量是溶液的3.18倍。Tan ⅡA-NLC可有效提高Tan ILA在表皮层的滞留量,具有广阔的应用前景。
To prepare Tan ⅡA loaded nanostructured lipid carrier(Tan ⅡA-NLC),and to study its in vitro skin distribution.The Tan ⅡA-NLC was prepared by high pressure homogenization technology and optimized by Box-Behnken design-response surface method,and it was characterized in terms of morphology,particle size,zeta potention,etc.The transdermal absorption of Tan DA-NLC was evaluated using Franz difiusion cells.The results showed that,the average particle size,PDI,zeta potential,EE and DL of Tan ⅡA-NLC prepared by optimal formulation(the drug/lipid materials ratio was 88,GMS/MCT ratio was 2,and emulsifier concentration was 1%) was.182 ± 14 nm,0.1906 ± 0.0245,-27.8± 5.4 mV,86.44 ± 9.26%,and 0.98 ± 0.18%,respectively.Compared with Tan ⅡA solution,Tan HA loaded NLC had lower amounts of Tan IIA penetrating through the skin after applying drug for 24 h,but had a 3.18 fold higher retention in the epidermis.These results indicate that the prepared Tan ⅡA-NLC has the ability to increase drug concentration in the epidermis,and has a broad application prospects.

引文

[1]中国药典.一部[S].2015:70.
    [2]Xu S,Liu P.Tanshinone II-A:new perspectives for old remedies[J].Expert Opin Ther Pat,2013,23(2):149.
    [3]李墨灵,张泽曦,杜天乐,等.丹参在皮肤科中的应用[J].中国美容医学,2015,24(14):79.
    [4]Li F L,Xu R,Zeng Q,et al.Tanshinone IIA Inhibits Growth of Keratinocytes through Cell Cycle Arrest and Apoptosis:Underlying Treatment Mechanism of Psoriasis[J].Evid Based Complement Alternat Med,2012,2012:927658
    [5]李玉萍,顾兵,刘建涛,熊向源,周春丽,吴光杰.丹参酮ILA的研究进展[J].时珍国医国药,2010,21(7):1772.
    [6]Hao H,Wang G,Cui N,et al.Pharmacokinetics,absorption and tissue distribution of tanshinone IIA solid dispersion[J].Plant Med,2006,72(14):1311.
    [7]Jana P,Aiman H,Rainer H,et al.Lipid nanoparticles(SLN,NLC)in cosmetic and pharmaceutical dermal products[J].Int J Pharm,2009,366(1-2):170.
    [8]Pardeike J,Schwabe K,Miiller R.Influence of nanostructured lipid carriers(NLC)on the physical properties of the Cutanova Nanorepari Q10 cream and the in vivo skin hydration effect[J].Int J Pharm,2010,396(1-2):166.
    [9]Muller R,Shegokar R,Keck C.20 years of lipid nanoparticles(SLN and NLC):present state of development and industrial applications[J].Curr Drug Discov Technol.2011,8(3):207.
    [10]Andrade L,Reis C,Maione L,et al.Impact of lipiddynamic behavior on physical stability in vitro release and skin permeation of genistein-loaded lipid nanoparticles[J].Eur J Pharm Biopharm,2014,(88):40.
    [11]Klang V,Schwarz J,Lenobel B,et al.In vitro vs in vivo tap esttipping:validation of the porcine ear model and penetration assessment of novel sucrose stearate emulsions[J].Eur J Pharm Biopharma.2012,80(3):604.